Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia

被引：13

作者：

George, Binsah ^{[1
]}

Kantarjian, Hagop ^{[1
]}

Jabbour, Elias ^{[1
]}

Jain, Nitin ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

来源：

IMMUNOTHERAPY | 2016年 / 8卷 / 02期

关键词：

acute lymphoblastic leukemia; antibody drug conjugate; inotuzumab; monoclonal antibody; ACUTE LYMPHOCYTIC-LEUKEMIA; ANTIBODY-TARGETED CHEMOTHERAPY; ACUTE MYELOID-LEUKEMIA; B-CELL LYMPHOMAS; HYPER-CVAD; GEMTUZUMAB OZOGAMICIN; CD22-TARGETED IMMUNOCONJUGATE; MONOCLONAL-ANTIBODY; ANTITUMOR EFFICACY; ADHESION MOLECULE;

D O I：

10.2217/imt.15.108

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Inotuzumab ozogamicin is a humanized anti-CD22 monoclonal antibody bound to a toxic natural calicheamicin, which is under investigation for the treatment of relapsed/refractory acute lymphoblastic leukemia. CD22 is commonly expressed in 90-100% of malignant mature B-lymphocyte lineage. The first Phase II study with inotuzumab ozogamicin conducted by Kantarjian et al. gave the opportunity for heavily pretreated patients with acute lymphoblastic leukemia to go for allogeneic stem cell transplant. Inotuzumab is well-tolerated with the exception of veno-occlusive disease. Overall inotuzumab ozogamicin is potentially an encouraging and promising therapy for patients.

引用

页码：135 / 143

页数：9

共 50 条

[11] Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia [J].

Luca Bertamini ;

Jacopo Nanni ;

Giovanni Marconi ;

Mariachiara Abbenante ;

Valentina Robustelli ;

Francesco Bacci ;

Antonella Matti ;

Stefania Paolini ;

Chiara Sartor ;

Silvia Lo Monaco ;

Maria Chiara Fontana ;

Stefano De Polo ;

Michele Cavo ;

Antonio Curti ;

Giovanni Martinelli ;

Cristina Papayannidis .

BMC Cancer, 18

[12] Results of the compassionate program of inotuzumab ozogamicin for adult patients with relapsed or refractory acute lymphoblastic leukemia in Spain [J].

Torrent, Anna ;

Morgades, Mireia ;

Garcia-Calduch, Olga ;

de Llano, Maria Paz Queipo ;

Montesinos, Pau ;

Navarro, Irene ;

Hernandez-Rivas, Jesus Maria ;

Barez-Garcia, Abelardo ;

Gonzalez-Campos, Jose ;

Oiartzabal, Itziar ;

Valero, Marta ;

Cervera, Marta ;

Zudaire, Teresa ;

Albors-Ferreiro, Manuel ;

Lopez-Godino, Oriana ;

Gil-Cortes, Cristina ;

Villalon, Lucia ;

Saldana, Raquel ;

Ribera, Josep-Maria .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2023, 111 (03) :485-490

[13] Characterizing the ideal patient for treatment with inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: a systematic literature review [J].

Marks, David I. ;

Cassaday, Ryan D. ;

Ribera, Josep-Maria ;

Schuh, Andre C. ;

Park, Jae H. ;

Chiaretti, Sabina ;

Stelljes, Matthias .

EXPERT REVIEW OF HEMATOLOGY, 2025, 18 (01) :91-103

[14] Inotuzumab ozogamicin versus standard of care in Asian patients with relapsed/refractory acute lymphoblastic leukemia [J].

Fujishima, Naohito ;

Uchida, Toshiki ;

Onishi, Yasushi ;

Jung, Chul Won ;

Goh, Yeow Tee ;

Ando, Kiyoshi ;

Wang, Ming Chung ;

Ono, Chiho ;

Matsumizu, Miyako ;

Paccagnella, M. Luisa ;

Sleight, Barbara ;

Vandendries, Erik ;

Fujii, Yosuke ;

Hino, Masayuki .

INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 110 (06) :709-722

[15] Inotuzumab Ozogamicin Salvage Monotherapy for the Treatment of Relapsed/Refractory Acute B-Cell Lymphoblastic Leukemia [J].

Darcin, Tahir ;

Yigenoglu, Tugce Nur ;

Sahin, Derya ;

Bakirtas, Mehmet ;

Basci, Semih ;

Merdin, Alparslan ;

Yildiz, Jale ;

Ulu, Bahar Uncu ;

Tetik, Aysegul ;

Iskender, Dicle ;

Cakar, Merih Kizil ;

Dal, Mehmet Sinan ;

Altuntas, Fevzi .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 :S192-S193

[16] Profile of inotuzumab ozogamicin and its potential in the treatment of acute lymphoblastic leukemia [J].

Thomas, Xavier .

BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY, 2014, 4 :1-8

[17] Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia [J].

Marks, David, I ;

Kebriaei, Partow ;

Stelljes, Matthias ;

Goekbuget, Nicola ;

Kantarjian, Hagop ;

Advani, Anjali S. ;

Merchant, Akil ;

Stock, Wendy ;

Cassaday, Ryan D. ;

Wang, Tao ;

Zhang, Hui ;

Loberiza, Fausto ;

Vandendries, Erik ;

DeAngelo, Daniel J. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (09) :1720-1729

[18] Inotuzumab ozogamicin versus standard of care in Asian patients with relapsed/refractory acute lymphoblastic leukemia [J].

Naohito Fujishima ;

Toshiki Uchida ;

Yasushi Onishi ;

Chul Won Jung ;

Yeow Tee Goh ;

Kiyoshi Ando ;

Ming Chung Wang ;

Chiho Ono ;

Miyako Matsumizu ;

M. Luisa Paccagnella ;

Barbara Sleight ;

Erik Vandendries ;

Yosuke Fujii ;

Masayuki Hino .

International Journal of Hematology, 2019, 110 :709-722

[19] The clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemia [J].

Yilmaz, Musa ;

Richard, Samantha ;

Jabbour, Elias .

THERAPEUTIC ADVANCES IN HEMATOLOGY, 2015, 6 (05) :253-261

[20] Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia [J].

Stock, Wendy ;

Martinelli, Giovanni ;

Stelljes, Matthias ;

DeAngelo, Daniel J. ;

Goekbuget, Nicola ;

Advani, Anjali S. ;

O'Brien, Susan ;

Liedtke, Michaela ;

Merchant, Akil A. ;

Cassaday, Ryan D. ;

Wang, Tao ;

Zhang, Hui ;

Vandendries, Erik ;

Jabbour, Elias ;

Marks, David, I ;

Kantarjian, Hagop M. .

CANCER, 2021, 127 (06) :905-913

← 1 2 3 4 5 →